UP!
 |
|
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: ACOR S&P 600 Component FWB: CDG |
| Industry | Health care Biotechnology |
| Founded | 1995 (1995) |
| Founder | Ron Cohen |
| Headquarters | Ardsley, New York, United States |
|
Key people
|
Ron Cohen (CEO) Andrew R. Blight |
| Products | Zanaflex Ampyra Qutenza |
| Revenue |  US$292.2 Million (FY 2011) |
|
Operating income
|
US$35.1 Million (FY 2011) |
|
Net income
|
US$30.6 Million (FY 2011) |
| Total assets | US$379.5 Million (FY 2011) |
| Total equity | US$205.2 Million (FY 2011) |
|
Number of employees
|
328 (February, 2012) |
| Website | Acorda.com |
Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.
In September 2014 the company acquired Civitas Therapeutics for $525 million - gaining the Phase III Parkinson’s drug, CVT-301.
In January 2016, the company acquired Finnish pharmaceutical company, Biotie Therapies, for $363 million. This gave the company control over Biotes sclerosing cholangitis drug, BTT1023.
In November 2016, Acorda Therapeutics announced it was discontinuing development of dalfampridine, a drug intended for post-stroke walking difficulties, after a clinical trial failure. The discontinuation of the drug caused Acorda's shares to drop as much as 13.2%. Acorda shares have dropped 50.2% since January 2016.
As of November 5, 2017, the members of the board of directors of Acorda Therapeutics were: Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, Ian F. Smith, and Catherine Strader.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q2 2022 | 2022-08-04 | 0.00 | 0.00 |
| Q1 2022 | 2022-05-11 | 0.00 | 0.00 |
| Q4 2021 | 2022-03-09 | 0.00 | 0.00 |
| Q3 2021 | 2021-11-09 | -1.43 | -1.43 |
| Q2 2021 | 2021-08-05 | -1.87 | -1.87 |
| Q1 2021 | 2021-05-06 | -2.46 | -2.46 |
| Q4 2020 | 2021-03-04 | -2.50 | -2.50 |
| Q3 2020 | 2020-10-21 | 0.00 | 0.00 |
| Q2 2020 | 2020-08-04 | -0.35 | -0.37 |
| Q1 2020 | 2020-05-05 | -0.51 | -0.14 |
| 2016-06-01 | Boost Price Target | Aegis | Buy | $40.00 to $52.00 |
| 2016-05-22 | Reiterated Rating | Leerink Swann | Hold | $31.00 to $29.00 |
| 2016-05-20 | Reiterated Rating | Cowen and Company | Outperform | $65.00 to $60.00 |
| 2016-05-20 | Reiterated Rating | Evercore ISI | Hold | $32.00 |
| 2016-04-28 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-04-17 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-03-30 | Initiated Coverage | Goldman Sachs | Sell | $23.00 |
| 2016-03-30 | Initiated Coverage | Goldman Sachs Group Inc. | Sell | $23.00 |
| 2016-03-14 | Lower Price Target | Stifel Nicolaus | Buy | $48.00 |
| 2016-02-12 | Reiterated Rating | Stifel Nicolaus | Buy | $53.00 |
| 2016-01-19 | Reiterated Rating | Leerink Swann | Market Perform | $35.00 |
| 2016-01-13 | Reiterated Rating | Cowen and Company | Outperform | $65.00 |
| 2016-01-11 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | |
| 2016-01-06 | Boost Price Target | Aegis | Buy | $40.00 to $52.00 |
| 2015-10-23 | Reiterated Rating | Aegis | Buy | $40.00 |
| 2015-10-22 | Reiterated Rating | JPMorgan Chase & Co. | Hold | $42.00 |
| 2015-10-05 | Reiterated Rating | Leerink Swann | Hold | |
| 2015-10-05 | Reiterated Rating | Cowen and Company | Buy | $65.00 |
| 2015-09-01 | Initiated Coverage | Aegis | Buy | $40.00 |
| 2015-08-31 | Initiated Coverage | Raymond James | Market Perform | |
| 2015-08-31 | Initiated Coverage | Raymond James Financial Inc. | Market Perform | |
| 2015-08-25 | Reiterated Rating | Stifel Nicolaus | Buy | $47.00 |
| 2015-08-25 | Reiterated Rating | Cowen and Company | Outperform | $65.00 |
| 2015-08-25 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | |
| 2015-07-31 | Reiterated Rating | Canaccord Genuity | Hold | $32.00 |
| 2015-07-31 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $42.00 |
| 2015-07-30 | Reiterated Rating | Cowen and Company | Outperform | $65.00 |
| 2015-06-22 | Set Price Target | MLV & Co. | Buy | $58.00 |
| 2015-06-09 | Initiated Coverage | Guggenheim | Neutral | |
| 2015-05-27 | Reiterated Rating | Canaccord Genuity | Hold | $30.00 |
| 2015-05-15 | Reiterated Rating | Canaccord Genuity | Hold | $30.00 |
| 2015-05-01 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $42.00 |
| 2015-05-01 | Reiterated Rating | Canaccord Genuity | Hold | $30.00 |
| 2015-04-22 | Initiated Coverage | Piper Jaffray | Neutral | |
| 2015-04-22 | Initiated Coverage | Piper Jaffray Cos. | Neutral | |
| 2015-02-15 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $42.00 |
| 2015-02-15 | Reiterated Rating | Canaccord Genuity | Hold | $30.00 |
| 2015-02-13 | Reiterated Rating | Citigroup Inc. | Hold | $46.00 to $42.00 |
| 2015-02-12 | Initiated Coverage | MLV & Co. | Buy | $58.00 |
| 2015-02-11 | Set Price Target | RBC Capital | Buy | $45.00 |
| 2015-02-11 | Set Price Target | Royal Bank Of Canada | Buy | $45.00 |
| 2015-01-13 | Reiterated Rating | Citigroup Inc. | Hold | $36.00 to $46.00 |
| 2015-01-12 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | |
| 2015-01-05 | Set Price Target | JPMorgan Chase & Co. | Hold | $42.00 |
| 2014-12-26 | Reiterated Rating | Aegis | Buy | |
| 2014-12-04 | Initiated Coverage | Goldman Sachs | Neutral | $40.00 |
| 2014-10-31 | Reiterated Rating | FBR & Co. | Outperform | $57.00 to $59.00 |
| 2014-10-31 | Reiterated Rating | Citigroup Inc. | Neutral | $34.00 to $36.00 |
| 2014-10-31 | Reiterated Rating | FBR & Co | Outperform | $57.00 to $59.00 |
| 2014-10-30 | Boost Price Target | MKM Partners | Neutral | $31.50 to $33.00 |
| 2014-08-19 | Resumed | Stifel | Buy | $47 |
| 2014-08-19 | Initiated Coverage | Stifel Nicolaus | Buy | $47.00 |
| 2014-05-07 | Lower Price Target | MKM Partners | Neutral | $33.00 to $31.50 |
| 2014-05-06 | Reiterated Rating | Aegis | Buy | |
| 2014-05-05 | Reiterated Rating | Citigroup Inc. | Hold | $34.00 |
| 2014-04-21 | Upgrade | Ned Davis Research | Sell to Neutral | |
| 2014-04-17 | Initiated Coverage | Canaccord Genuity | Hold | $37.00 |
| 2014-04-14 | Upgrade | FBR Capital | Mkt Perform to Outperform | $30 to $47 |
| 2014-04-14 | Upgrade | FBR & Co. | Market Perform to Outperform | $30.00 to $47.00 |
| 2014-01-06 | Downgrade | Citigroup Inc. | Buy to Neutral | $37.00 to $33.00 |
| 2013-11-01 | Upgrade | MKM Partners | Sell to Neutral | $33.00 to $32.00 |
| 2013-11-01 | Reiterated | FBR Capital | Outperform | $35 to $30 |
| 2013-11-01 | Lower Price Target | FBR & Co. | Outperform | $35.00 to $30.00 |
| 2013-10-30 | Initiated | FBR Capital | Mkt Perform | $35 |
| 2013-10-30 | Initiated Coverage | FBR & Co. | Market Perform | $35.00 |
| 2013-10-01 | Reiterated | Aegis Capital | Buy | $43 to $50 |
| 2013-10-01 | Boost Price Target | Aegis | Buy | $43.00 to $50.00 |
| 2013-08-01 | Reiterated | Feltl & Co. | Buy | $40 to $43 |
| 2013-05-02 | Downgrade | MKM Partners | Neutral to Sell | |
| 2013-04-16 | Reiterated | MKM Partners | Neutral | $31 to $33 |
| 2013-04-15 | Reiterated | Aegis Capital | Buy | $34 to $40 |
| 2013-01-08 | Downgrade | MKM Partners | Buy to Neutral | |
| 2012-03-15 | Resumed | Stifel Nicolaus | Buy | $34 |
| 2012-01-09 | Upgrade | MKM Partners | Neutral to Buy | $26 to $32 |
| 2011-09-20 | Initiated | MKM Partners | Neutral | $25 |
| 2011-04-20 | Reiterated | RBC Capital Mkts | Outperform | $32 to $38 |
| 2010-12-14 | Downgrade | Robert W. Baird | Outperform to Neutral | $40 to $31 |
| 2010-09-09 | Initiated | Stifel Nicolaus | Buy | $39 |
| 2010-09-07 | Upgrade | Robert W. Baird | Neutral to Outperform | $40 |
| 2010-04-15 | Reiterated | RBC Capital Mkts | Outperform | $36 to $40 |
| 2010-03-29 | Initiated | Citigroup | Hold | |
| 2010-02-17 | Reiterated | RBC Capital Mkts | Outperform | $30 to $36 |
| 2010-02-04 | Downgrade | Robert W. Baird | Outperform to Neutral | $32 |
| 2016-06-01 | Boost Price Target | Aegis | Buy | $40.00 to $52.00 |
| 2016-05-22 | Reiterated Rating | Leerink Swann | Hold | $31.00 to $29.00 |
| 2016-05-20 | Reiterated Rating | Cowen and Company | Outperform | $65.00 to $60.00 |
| 2016-05-20 | Reiterated Rating | Evercore ISI | Hold | $32.00 |
| 2016-04-28 | Reiterated Rating | Cowen and Company | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ACOR 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| SCOPIA FUND MANAGEMENT, LLC | 20.30% (8474728) | ACOR / ITRI / PHH / |
| COHEN RON President and CEO | 1.35% (564285) | ACOR / DYAX / |
| Wasman Jane Exec VP, General Counsel & Sec | 0.26% (106809) | ACOR / GALE / |
| Blight Andrew Chief Scientifc Officer | 0.19% (78594) | ACOR / |
| Batycky Richard P. Chief Tech. Off. & Site Head | 0.13% (55513) | ACOR / |
| Hindman Andrew A. Chief Business Dev. Officer | 0.12% (51048) | ACOR / |
| ROGERS MICHAEL W Chief Financial Officer | 0.10% (40713) | ACOR / BGMD / CNDO / KERX / PSDV / |
| Wessel Thomas Chief Medical Officer | 0.09% (36350) | ACOR / |
| BLANK BURKHARD Chief Medical Officer | 0.08% (33150) | ACOR / |
| Carrazana Enrique J. Chief Medical Officer | 0.08% (32148) | ACOR / MRNS / |
| Sabella Lauren M Exec. VP-Commercial Dvlpmnt | 0.04% (18453) | ACOR / |
| LAWRENCE DAVID Chief Financial Officer | 0.02% (8124) | ACOR / |
| PANEM SANDRA PHD | 0.01% (2912) | ACOR / |
UM